PHIO - Phio Pharmaceuticals Corp.
NASDAQ
->
Healthcare
->
Biotechnology
Marlborough,
United States
Type: Equity
PHIO price evolution
PHIO
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.7 | $6.47 | $8.49 | $8.46 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $5.29 | $6.85 | $9.32 | $9.33 |
| Long term investments | ||||
| Property, plant & equipment | $0 | $0 | $0.04 | $0.21 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0 | $0.01 | $0.04 | $0.21 |
| Total investments | ||||
| Total assets | $5.3 | $6.85 | $9.36 | $9.54 |
| Current liabilities | ||||
| Accounts payable | $0.34 | $0.32 | $0.66 | $0.17 |
| Deferred revenue | ||||
| Short long term debt | $0.04 | $0.07 | ||
| Total current liabilities | $1.52 | $1.25 | $1.63 | $2.33 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.04 | $0.07 | ||
| Total liabilities | $1.52 | $1.25 | $1.63 | $2.33 |
| Shareholders' equity | ||||
| Retained earnings | -$143.21 | -$141.36 | -$139.21 | -$137.31 |
| Other shareholder equity | -$0 | -$0 | -$0 | -$0 |
| Total shareholder equity | $3.77 | $5.6 | $7.73 | $7.21 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8.49 | $11.83 | $24.11 | $14.29 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $9.32 | $12.45 | $24.73 | $15.16 |
| Long term investments | ||||
| Property, plant & equipment | $0.04 | $0.34 | $0.42 | $0.56 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.04 | $0.37 | $0.44 | $0.57 |
| Total investments | ||||
| Total assets | $9.36 | $12.81 | $25.17 | $15.74 |
| Current liabilities | ||||
| Accounts payable | $0.66 | $0.78 | $0.28 | $0.73 |
| Deferred revenue | ||||
| Short long term debt | $0.04 | $0.14 | $0.13 | $0.12 |
| Total current liabilities | $1.63 | $1.94 | $3.07 | $2.2 |
| Long term debt | $0.04 | $0.17 | $0.53 | |
| Total noncurrent liabilities | $0.04 | $0.17 | $0.53 | |
| Total debt | $0.04 | $0.17 | $0.29 | $0.64 |
| Total liabilities | $1.63 | $1.97 | $3.24 | $2.72 |
| Shareholders' equity | ||||
| Retained earnings | -$139.21 | -$128.38 | -$116.9 | -$103.61 |
| Other shareholder equity | -$0 | |||
| Total shareholder equity | $7.73 | $10.84 | $21.93 | $13.02 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.87 | $1.15 | $1.01 | $1.81 |
| Selling, general & administrative | $1.05 | $1.06 | $0.77 | $0.97 |
| Total operating expenses | $1.91 | $2.21 | $1.9 | $2.78 |
| Operating income | -$1.91 | -$2.21 | -$1.9 | -$2.78 |
| Income from continuing operations | ||||
| EBIT | -$1.85 | -$2.15 | -$1.9 | -$2.78 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$1.85 | -$2.15 | -$1.9 | -$2.78 |
| Income (for common shares) | -$1.85 | -$2.15 | -$1.9 | -$2.78 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $6.33 | $7.01 | $8.89 | $4.43 |
| Selling, general & administrative | $4.37 | $4.45 | $4.63 | $4.36 |
| Total operating expenses | $10.82 | $11.46 | $13.51 | $8.79 |
| Operating income | -$10.82 | -$11.46 | -$13.51 | -$8.79 |
| Income from continuing operations | ||||
| EBIT | -$10.83 | -$11.48 | -$13.28 | -$8.79 |
| Income tax expense | ||||
| Interest expense | $0.01 | |||
| Net income | ||||
| Net income | -$10.83 | -$11.48 | -$13.29 | -$8.79 |
| Income (for common shares) | -$10.83 | -$11.48 | -$13.29 | -$8.79 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$1.85 | -$2.15 | -$1.9 | -$2.78 |
| Operating activities | ||||
| Depreciation | $0 | $0.03 | $0.04 | $0.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.01 | $0.03 | $0.01 | $0.09 |
| Total cash flows from operations | -$1.78 | -$2.01 | -$2.37 | -$2.9 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.4 | |||
| Net borrowings | ||||
| Total cash flows from financing | -$0 | $2.4 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.78 | -$2.02 | $0.03 | -$2.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$10.83 | -$11.48 | -$13.29 | -$8.79 |
| Operating activities | ||||
| Depreciation | $0.18 | $0.19 | $0.19 | $0.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.3 | $0.41 | $0.48 | $0.14 |
| Total cash flows from operations | -$10.75 | -$12.13 | -$11.86 | -$8.8 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.12 | -$0.05 | -$0.02 |
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.12 | -$0.05 | -$0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.44 | $21.72 | $15.93 | |
| Net borrowings | $0.2 | |||
| Total cash flows from financing | $7.41 | -$0.03 | $21.72 | $16.13 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.34 | -$12.28 | $9.81 | $7.31 |
News
Fundamentals
| Market cap | $1.33M |
|---|---|
| Enterprise value | -$3.37M |
| Shares outstanding | 510.19K |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$8.55M |
| EBIT | -$8.68M |
| Net Income | -$8.68M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.15 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | 0.39 |
| EV/EBIT | 0.39 |
| P/S ratio | N/A |
| P/B ratio | 0.35 |
| Book/Share | 7.40 |
| Cash/Share | 9.21 |
| EPS | -$17.00 |
|---|---|
| ROA | -111.75% |
| ROE | -142.68% |
| Debt/Equity | 0.21 |
|---|---|
| Net debt/EBITDA | 0.37 |
| Current ratio | 3.47 |
| Quick ratio | 3.47 |